E Andreopoulou
Overview
Explore the profile of E Andreopoulou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luen S, Salgado R, Dieci M, Vingiani A, Curigliano G, Gould R, et al.
Ann Oncol
. 2018 Dec;
30(2):236-242.
PMID: 30590484
Background: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated...
2.
Kalinsky K, Sparano J, Zhong X, Andreopoulou E, Taback B, Wiechmann L, et al.
Clin Transl Oncol
. 2018 May;
20(11):1474-1483.
PMID: 29736694
Introduction: The PI3K/AKT/mTOR pathway is an oncogenic driver in breast cancer (BC). In this multi-center, pre-surgical study, we evaluated the tissue effects of the AKT inhibitor MK-2206 in women with...
3.
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy B, et al.
Ann Oncol
. 2011 Oct;
23(5):1144-1150.
PMID: 21965473
Background: Circulating tumor cells (CTCs) are associated with inferior prognosis in metastatic breast cancer (MBC). We hypothesized that the relationship between CTCs and disease subtype would provide a better understanding...
4.
Andreopoulou E, Yang L, Rangel K, Reuben J, Hsu L, Krishnamurthy S, et al.
Int J Cancer
. 2011 Apr;
130(7):1590-7.
PMID: 21469140
The detection of CTCs prior to and during therapy is an independent and strong prognostic marker, and it is predictive of poor treatment outcome. A major challenge is that different...
5.
Kelly C, Pritchard K, Trudeau M, Andreopoulou E, Hess K, Pusztai L
Ann Oncol
. 2011 Mar;
22(11):2387-2393.
PMID: 21406473
Background: Recent retrospective studies have suggested that patients with T1a,bN0M0 human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at a higher risk for recurrence and might benefit from...
6.
Dawood S, Ueno N, Valero V, Andreopoulou E, Hsu L, Lara J, et al.
Ann Oncol
. 2010 May;
21(12):2348-2355.
PMID: 20439340
Background: The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC). Patients And Methods: Two hundred and...
7.
Mego M, De Giorgi U, Broglio K, Dawood S, Valero V, Andreopoulou E, et al.
Br J Cancer
. 2009 Nov;
101(11):1813-6.
PMID: 19888227
Background: Cancer is a risk factor for venous thromboembolism (VTE). Circulating tumour cells (CTCs) are an independent predictor of survival in metastatic breast cancer (MBC) patients. The aim of this...
8.
Mego M, De Giorgi U, Hsu L, Ueno N, Valero V, Jackson S, et al.
Ann Oncol
. 2009 Jun;
20(11):1824-8.
PMID: 19556320
Background: Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. Circulating tumor cells (CTCs) are an independent prognostic factor in metastatic breast cancer. The aim of this...
9.
Andreopoulou E, Yee H, Warycha M, Macari M, Berman R, Lowy A, et al.
J Chemother
. 2007 Sep;
19(4):451-4.
PMID: 17855191
The authors report and discuss a case of a mucinous carcinoma of the appendix, a rare entity with a distinct natural history that poses diagnostic and therapeutic challenges. Mucinous peritoneal...
10.
Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, et al.
Ann Oncol
. 2007 Feb;
18(4):716-21.
PMID: 17301073
Background: We hypothesized that a response to pegylated liposomal doxorubicin (PLD, Caelyx/Doxil) followed by maintenance is beneficial and safe in recurrent ovarian cancer. Patients And Methods: Sixteen patients have received...